• Astrazeneca plc, of London, said it will conduct two new trials designed to build scientific understanding of Brilinta (ticagrelor) tablets in additional high-risk patient populations. One trial involves 9,600 patients who have experienced an acute ischemic stroke or transient ischemic attack.